Journal article
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial
Abstract
BACKGROUND: Etripamil is a fast-acting, intranasally administered calcium-channel blocker in development for on-demand therapy outside a health-care setting for paroxysmal supraventricular tachycardia. We aimed to evaluate the efficacy and safety of etripamil 70 mg nasal spray using a symptom-prompted, repeat-dose regimen for acute conversion of atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm within 30 …
Authors
Stambler BS; Camm AJ; Alings M; Dorian P; Heidbuchel H; Houtgraaf J; Kowey PR; Merino JL; Mondésert B; Piccini JP
Journal
The Lancet, Vol. 402, No. 10396, pp. 118–128
Publisher
Elsevier
Publication Date
7 2023
DOI
10.1016/s0140-6736(23)00776-6
ISSN
0140-6736